Clinical Trial Update: Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial is planned to evaluate adding vorasidenib to temozolomide after radiation in patients with IDH-mutant, Grade 3 astrocytoma; recruitment has not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma Idh-mutant

Drugs mentioned

• Temozolomide (Temozolomide)
• Vorasidenib (vorasidenib)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Astrocytoma, IDH-Mutant, Grade 3 | Phase 3 | Status: NOT_YET_RECRUITING